河北医科大学学报

• 论著 • 上一篇    下一篇

雷珠单抗联合577 nm激光光凝治疗重度非增生型糖尿病视网膜病变伴黄斑水肿的效果观察

  

  1. 广东省深圳市第二人民医院眼科,广东 深圳 518000
  • 出版日期:2019-07-25 发布日期:2019-07-16
  • 作者简介:陈伽俐(1977-),女,广东揭阳人,广东省深圳市第二人民医院主治医师,医学学士,从事眼科疾病诊治研究。

Therapeutic effect of ranibizumab combined with 577 nm laser photocoagulation on severe nonproliferative diabetic retinopathy with macular edema#br#

  1. Department of Ophthalmology, the Second People′s Hospital of Shenzhen, Guangdong Province, Shenzhen 518000, China
  • Online:2019-07-25 Published:2019-07-16

摘要: [摘要]〓
〖HTH〗目的〖HTSS〗〖KG*2〗观察雷珠单抗联合577 nm激光光凝治疗重度非增生型糖尿病视网膜病变伴黄斑水肿的临床效果。
〖HTH〗方法〖HTSS〗〖KG*2〗将重度非增生型糖尿病视网膜病变伴黄斑水肿患者60例60眼随机分为观察组和对照组各30例30眼。观察组给予雷珠单抗联合577 nm激光光凝治疗,对照组给予577 nm激光光凝治疗。于治疗后1周、1个月、3个月及6个月复查光学相干断层扫描和荧光素眼底血管造影,比较2组最佳矫正视力、黄斑中心凹视网膜神经上皮厚度、黄斑区6 mm直径神经上皮总体容积,以及治疗过程中的激光能量、能量密度、光斑数及并发症发生情况。
〖HTH〗结果〖HTSS〗〖KG*2〗随时间延长,2组最佳矫正视力呈升高趋势,黄斑中心凹视网膜神经上皮厚度及黄斑区6mm直径神经上皮总体容积呈降低趋势,观察组最佳矫正视力高于对照组,黄斑中心凹视网膜神经上皮厚度及黄斑区6mm直径神经上皮总体容积低于对照组,其组间、时点间、组间与时点间交互作用差异均有统计学意义(P<005);观察组激光能量、光斑数、能量密度显著低于对照组(P<005);2组均未发生严重并发症。
〖HTH〗结论〖HTSS〗〖KG*2〗雷珠单抗联合577 nm激光光凝治疗重度非增生型糖尿病视网膜病变伴黄斑水肿的效果肯定,较为安全。

关键词: 糖尿病视网膜病变, 黄斑水肿, 雷珠单抗, 激光疗法

Abstract: [Abstract]〓Objective〖HTSS〗〓To observe the clinical efficacy of ranibizumab combined with 577 nm laser photocoagulation for severe nonproliferative diabetic retinopathy with macular edema.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓 Sixty patients and 60 eyes with severe nonproliferative diabetic retinopathy with macular edema were randomly divided into observation group and control group, 30 cases and 30 eyes respectively. The observation group was given ranibizumab in combination with 577 nm laser photocoagulation, and the control group was given 577 nm laser photocoagulation. Optical coherence tomography and fluorescein fundus angiography were reexamined 1 week, 1 month, 3 months and 6 months after treatment. The best corrected visual acuity before and after treatment, the thickness of the foveal retinal neuroepithelial foci of the macula and the total volume of the neuroepithelial lesion of the 6 mm diameter in the macular area were recorded and compared. The laser energy, energy density, number of spots and complications were compared between the two groups.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓With the extension of time, the best corrected visual acuity of two groups were significantly increased, the macular foveal retinal neuroepithelial thickness and macular area 6 mm diameter neuroepithelial overall volume of two groups were significantly decreased. The best corrected vision of observation group was higher than the control group, macular foveal retinal neuroepithelial thickness and macular area 6 mm diameter neuroepithelial overall volume were lower than the control group, There were significant differences in interaction among groups, time points and time points between groups(P<005). The laser energy, spot number and energy density of the observation group were lower than that of the control group (P<005). No serious complications occurred in either group. 〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓The efficacy of ranibizumab combined with 577 nm laser photocoagulation for severe nonproliferative diabetic retinopathy with macular edema is positive and clinically safe.

Key words: diabetic retinopathy, macular edema, rayuzumab, laser therapy